Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial
2015
NCT02364986
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

DZNE, Bonn

Active Ingredients

Drugs in Phase 1 Trials (1)

interferon beta-1b (betaseron) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 1)

Multiple Sclerosis, Relapsing-Remitting (Phase 1)

Sclerosis (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1